切换至 "中华医学电子期刊资源库"

中华妇幼临床医学杂志(电子版) ›› 2018, Vol. 14 ›› Issue (06) : 718 -723. doi: 10.3877/cma.j.issn.1673-5250.2018.06.015

所属专题: 文献

论著

高龄孕妇产前诊断结果及其首选无创产前筛查局限性的大样本分析
苏杭1, 刘之英1, 赖怡1, 秦利1, 刘红倩1, 张雪梅1, 祝倩1, 胡婷1, 张迅1, 赵小文1, 刘珊玲1, 王和1,()   
  1. 1. 610041 成都,四川大学华西第二医院妇产科产前诊断中心、出生缺陷与相关妇儿疾病教育部重点实验室
  • 收稿日期:2018-04-28 修回日期:2018-09-22 出版日期:2018-12-01
  • 通信作者: 王和

Prenatal diagnosis results of advanced maternal age women and limitations of preferred non-invasive prenatal screening to them: a large sample analysis

Hang Su1, Zhiying Liu1, Yi Lai1, Li Qin1, Hongqian Liu1, Xuemei Zhang1, Qian Zhu1, Ting Hu1, Xun Zhang1, Xiaowen Zhao1, Shanling Liu1, He Wang1,()   

  1. 1. Department of Prenatal Diagnosis of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
  • Received:2018-04-28 Revised:2018-09-22 Published:2018-12-01
  • Corresponding author: He Wang
  • About author:
    Corresponding author: Wang He, Email:
  • Supported by:
    National Science and Technology Infrastructure Program(2014BAI06B03)
引用本文:

苏杭, 刘之英, 赖怡, 秦利, 刘红倩, 张雪梅, 祝倩, 胡婷, 张迅, 赵小文, 刘珊玲, 王和. 高龄孕妇产前诊断结果及其首选无创产前筛查局限性的大样本分析[J]. 中华妇幼临床医学杂志(电子版), 2018, 14(06): 718-723.

Hang Su, Zhiying Liu, Yi Lai, Li Qin, Hongqian Liu, Xuemei Zhang, Qian Zhu, Ting Hu, Xun Zhang, Xiaowen Zhao, Shanling Liu, He Wang. Prenatal diagnosis results of advanced maternal age women and limitations of preferred non-invasive prenatal screening to them: a large sample analysis[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2018, 14(06): 718-723.

目的

探讨高龄(预产期年龄≥35岁)孕妇产前诊断应用无创产前筛查(NIPS)的价值,以及首选NIPS的局限性。

方法

选择2009年1月至2013年12月,于四川大学华西第二医院接受产前诊断的20 751例高龄孕妇为研究对象。采用回顾性分析方法,对其羊水穿刺胎儿细胞遗传学产前诊断结果进行分析,对胎儿染色体异常进行分类,计算各类染色体异常所占比例。本研究遵循的程序符合2013年修订的《世界医学协会赫尔辛基宣言》要求。

结果

这20 751例高龄孕妇产前诊断结果显示:①胎儿的细胞遗传学产前诊断,检出染色体异常为380例,检出率为1.83%(380/20 751)。其中,21-、18-及13-三体综合征胎儿分别为173例(45.53%,173/380),51例(13.42%,51/380)及9例(2.37%,9/380),总计为233例(61.32%);性染色体异常胎儿为78例(20.53%,78/380),染色体异常携带者为49例(12.89%,49/380),其他染色体异常胎儿为20例(5.26%,20/380),总计为147例(38.68%)。如果首先采取NIPS进行产前诊断,则检测胎儿的目标疾病为21-、18-、13-三体综合征,可检出的胎儿染色体异常仅占全部有临床表型的染色体异常胎儿总数的70.39%(233/331)。②2009—2013年,胎儿染色体异常检出率依次为1.49%(38/2 543)、1.44%(51/3 548)、1.87%(87/4 651)、1.85%(99/5 345)、2.25%(105/4 664),胎儿染色体异常检出率整体呈逐年上升趋势。

结论

NIPS作为产前诊断的一线检测手段,首选该技术筛查胎儿染色体异常,尤其是对于高龄孕妇具有局限性,应该慎重。

Objective

Based on the analysis of the cytogenetic prenatal diagnosis results, the values of non-invasive prenatal screening (NIPS) were analyzed in the detection of the advanced maternal age women (≥35 years old) and limitations of preferred to NIPS according to the fetal chromosomal abnormalities.

Methods

From January 2009 to December 2013, a total of 20 751 advanced maternal age women who received prenatal diagnosis in West China Second University Hospital, Sichuan University were selected as research subjects. The results of the fetal cytogenetic prenatal diagnosis by amniocentesis of those 20 751 advanced maternal age women were analyzed retrospectively. The chromosome abnormalities of the fetus were classified and the proportions of all kinds of chromosome abnormalities were calculated. This research was in line with the requirements of World Medical Association Declaration of Helsinki revised in 2013.

Results

① A total of 380 chromosome abnormalities were detected among those 20 751 advanced maternal age women according to the results of the cytogenetic prenatal diagnosis. The total detection rate of chromosome abnormalities in advanced maternal age women was 1.83% (380/20 751), including 173 cases of trisomy 21 (45.53%, 173/380), 51 cases of trisomy 18 (13.42%, 51/380), 9 cases of trisomy 13 (2.37%, 9/380), 78 cases of sex chromosome abnormalities (20.53%, 78/380), 49 carriers of chromosomal abnormality (12.89%, 49/380), 20 cases of other chromosome abnormalities (5.26%, 20/380). If NIPS was used as the preferred prenatal diagnosis method, then the aimed diseases of NIPT detecting were trisomy 21, trisomy 18 and trisomy 13, so the chromosome abnormalities which could be detected out would probably account for 70.39% (233/331) of all chromosomal abnormalities with clinical phenotypes. ②From 2009 to 2013, the detection rates of fetal chromosomal abnormalities were 1.49% (38/2 543), 1.44% (51/3 548), 1.87% (87/4 651), 1.85% (99/5 345), and 2.25% (105/4 664), respectively, and the detection rate of fetal chromosomal abnormalities was increasing year by year.

Conclusion

NIPS as the preferred detection method for screening of fetal chromosomal abnormalities in advanced maternal age women should be cautiously used.

表1 380例胎儿染色体异常分类、检出率及其构成比分析结果[%(n/n′)]
表2 380例染色体异常胎儿的染色体核型及其构成比[例数(%)]
染色体核型 构成比 染色体核型 构成比
21-三体综合征 173(45.53) ? 46,X,inv(X) 1(0.26)
? 47,XX(XY),+21 173(45.53) ? 46,XX,t(1;16)(q10;p10)mat 1(0.26)
18-三体综合征 51(13.42) ? 46,XX,t(1;9)(p35;p11)pat 1(0.26)
? 47,XX(XY),+18 51(13.42) ? 46,XX,t(11;22)(q24;q13) 1(0.26)
13-三体综合征 9(2.37) ? 46,xx,t(12;18)(q21;q12) 1(0.26)
? 47,XX(XY),+13 9(2.37) ? 46,XX,t(2;12)(q11;q11)mat 1(0.26)
性染色体异常 78(20.53) ? 46,XX,t(2;15)(q22;q24),9qh+ 1(0.26)
? 45,X 6(1.58) ? 46,XX,t(4;5)(q28;q23) 1(0.26)
? 45,X,[9]/47,XXX[5]/46,XX[6] 1(0.26) ? 46,XX,t(4;8)(q21;p11) 1(0.26)
? 45,X,inv9 1(0.26) ? 46,XX,t(5;15)(q23;q25) 1(0.26)
? 45,X[4]/46,XX[97] 1(0.26) ? 46,XX,t(6;19)(p11;q11)mat 1(0.26)
? 45,X[1]/46,XXY[1]/46,XY[34] 1(0.26) ? 46,XX,t(8;10)(q23;p25)pat 1(0.26)
? 45,X[3]/46,X,i(X)(q10)[21] 1(0.26) ? 46,XX,t(8;22)(q24.2;q12)mat 1(0.26)
? 45,X[3]/46,XX[17] 1(0.26) ? 46,XX,t(9;10)(q21;p12) 1(0.26)
? 45,X[3]/46,XY[27] 1(0.26) ? 46,XX,t(9;14)(q32;q31)mat 1(0.26)
? 45,X[4]/46,XX[32] 1(0.26) ? 46,XY,der(10)(q?) 1(0.26)
? 45,X[4]/46,XY[28] 1(0.26) ? 46,XY,t(1;2)(p31;q21) 1(0.26)
? 45,X[5]/46,XX[30] 1(0.26) ? 46,XY,t(1;4)(q31;p12) 1(0.26)
? 45,X[7]/46,X,i(X)(q10)[13] 1(0.26) ? 46,XY,t(10;13)(q11;q33) 1(0.26)
? 45,X[7]/46,XX[27] 1(0.26) ? 46,XY,t(12;16)(p12;p12)pat 1(0.26)
? 45,X[7]/46,XY[31] 1(0.26) ? 46,XY,t(19;20)(p13;q22)pat 1(0.26)
? 45,X[9]/46,XX[11] 1(0.26) ? 46,XY,t(2;11)[5]/46,XY[27] 1(0.26)
? 46,X,del(X)(p21→ter) 1(0.26) ? 46,XY,t(2;15)(p14;q24) mat 1(0.26)
? 46,X,i(X) 1(0.26) ? 46,XY,t(2;18)(q34;p11) 1(0.26)
? 46,X,i(Xq) 1(0.26) ? 46,XY,t(4:18)(q21;q23)mat 1(0.26)
? 46,XX[5]/46,XY,[25] 1(0.26) ? 46,XY,t(5;7)(q22;p22) 1(0.26)
? 46,XY[27]/46,XX[14] 1(0.26) ? 46,XY,t(6;13)(q14;q33) 1(0.26)
? 47,XXX[5]/46,XX[15] 1(0.26) ? 46,XY,t(8;12)(q23;q13)[11]/46,XY[19] 1(0.26)
? 47,XXX 12(3.16) ? 46,XY,t(8;15)(p23;q22) 1(0.26)
? 47,XXX[12]/45,X[5] 1(0.26) ? 46,XY,t(3;15)(q22;q22) 1(0.26)
? 47,XXX[5]/46,XX[18] 1(0.26) ? 46,XX,t(2;4)(q21;q32) 1(0.26)
? 47,XXY 25(6.58) ? 46,XX,t(6;9)(p10′p10) 1(0.26)
? 47,XXY[10]/46,XY[29] 1(0.26) ? 46,XY,t(X;3)(q21;q21)mat 1(0.26)
? 47,XXY[19]/46,XY[14] 1(0.26) 其他染色体异常 20(5.26)
? 47,XYY 6(1.58) ? 46,XX,del(18)(q21) 1(0.26)
? 47,XYY,inv9 1(0.26) ? 46,XX,der(17) 1(0.26)
? 47,XYY[6]/46,XY[14] 1(0.26) ? 46,XX,der(18)(p?) 1(0.26)
? 47,XYY[14]/46,XY[13] 1(0.26) ? 46,XX,der(4)(p?) 1(0.26)
? 47,XYY[3]/46,XY[35] 1(0.26) ? 46,XY,del(11)(q?) 1(0.26)
? 47,XYY[4]/46,XY[35] 1(0.26) ? 46,XY,del(21)(qter→p10) 2(0.53)
染色体异常携带者 49(12.89) ? 47,XY,+22[3]/46,XY[83] 1(0.26)
? 45,XX,rob(13;14)(q10;q10) 3(0.79) ? 47,XX,+16[6]/46,XX[20] 1(0.26)
? 45,XX,rob(13;14)(q10;q10)pat 1(0.26) ? 47,XX,+4[2]/46,XX[28] 1(0.26)
? 45,XX,rob(13;21)(q10;q10) 1(0.26) ? 47,XX,+7[3]/46,XY[3] 1(0.26)
? 45,XX,rob(14;22)(q10;q10) 2(0.53) ? 47,XX,+9 1(0.26)
? 45,XX,rob(15;22)(q10;q10)[23]/46,XX[7] 1(0.26) ? 47,XY,+2[2]/46,XY[33] 1(0.26)
? 45,XX,rob(15;22)(q10;q10)pat 1(0.26) ? 47,XY,+2[2]/46,XY[36] 1(0.26)
? 45,XY,rob(13;14)(q10;q10)mat 2(0.53) ? 47,XY,+20[13]/46,XY[17] 1(0.26)
? 45,XY,rob(13;14)(q10;q10) 1(0.26) ? 47,XY,+20[5]/46,XY[46] 1(0.26)
? 45,XY,rob(14;21)(q10;q10)pat 1(0.26) ? 47,XY,+4[3]/46,XY[32] 1(0.26)
? 45,XY,rob(14;21)(q10;q10) 1(0.26) ? 47,XY,+M[8]/46,XY[2] 1(0.26)
? 45,XY,rob(14;22)(q10;q10) 1(0.26) ? 47,XY,+mar 1(0.26)
? 45,XY,rob(13;14)(q10;q10) 1(0.26) ? 47,XY,+mar[4]/46,XY[10] 1(0.26)
图1 2009-2013年20 751例高龄孕妇中,不同年份胎儿染色体异常检出率折线图
[1]
郑静,卓越,孙大康,等. 不同年龄段孕妇无创DNA产前检测结果对比分析[J].中国妇幼保健,2015,30(36):6538-6540.
[2]
季修庆,蒋涛,林颖,等. 无创产前检测在高龄孕妇产前筛查唐氏综合征中的应用[J].临床检验杂志,2015, 33(5):325-327.
[3]
国家卫生计生委办公厅. 国家卫生计生委办公厅关于规范有序开展孕妇外周血胎儿游离DNA产前筛查与诊断工作的通知(国卫办妇幼发[2016] 45号)[EB/OL]. (2016-10-27) [2018-08-10].

URL    
[4]
Kuliev A, Verlinsky Y. The role of preimplantation genetic diagnosis in women of advanced reproductive age[J]. Curr Opin Obstet Gynecol, 2003, 15(3): 233-238.
[5]
Kong CW, Leung TN, Lung TY, et al. Risk factors for procedure related fetal losses after midtrimester genetic amniocentesis[J]. Prenat Diagn, 2006, 26(10): 925-930.
[6]
Tesng JJ, Chou MM, Lo FC, et al. Detection of chromosome aberrations in the second trimester using genetic amniocentesis: experience during 1995-2004[J]. Taiwan J Obstet Gynecol, 2006, 45(1): 39-41.
[7]
石庆华,许波,杨庆岭,等. 非整倍体和人类生殖健康[J]. 中国科学技术大学学报,2008, 38(8): 883-889.
[8]
Liang X, Ma J, Schatten H, et al. Epigenetic changes associated with oocyte aging[J]. Sci China Life Sci, 2012, 55(8): 670-676.
[9]
Alexander E, Kelly S, Kerzin-Storrar L. Non-invasive prenatal testing: UK genetic counselors′ experiences and perspectives[J].J Genet Couns, 2015, 24(2): 300-311.
[10]
Dan S, Wang W, Ren JH, et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11 105 pregnancies with mixed risk factors[J]. Prenat Diagn, 2012, 32(13): 1225-1232.
[11]
Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study[J]. Genet Med, 2011, 13(11): 913-920.
[12]
Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study[J]. BMJ, 2011, 342(7790): c7401.
[13]
Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting[J]. Am J Obstet Gynecol, 2011, 204(3): 205.e1-205.e11.
[14]
Sehnert AJ, Rhees B, Comstock D, et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood[J]. Chin Chem, 2011, 57(7): 1042-1049.
[15]
Sparks AB, Struble CA, Wang ET, et al. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18[J]. Am J Obstet Gynecol, 2012, 206(4): 319. e1-319. e9.
[16]
Norton ME, Brar H, Weiss J, et al. Non-invasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18[J]. Am J Obstet Gynecol, 2012, 207(2): 137. e1-137. e8.
[17]
Bianchi DW, Platt LD, Coldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing[J]. Obstet Gynecol, 2012, 119(5): 890-901.
[18]
Ashoor G, Syngelaki A, Wagner M, et al. Chromosome-selective sequencing of maternal plasma cell–free DNA for first-trimester detection of trisomy 21 and trisomy 18[J]. Am J Obstet Gynecol, 2012, 206(4): 322. e1-322. e5.
[19]
Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy[J].Genet Med, 2013, 15(5): 395-398.
[20]
Canick JA, Palomaki GE, Kloza EM, et al. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies[J]. Prenat Diagn, 2013, 33(7): 667-674.
[21]
Vora NL, Johnson KL, Basu S, et al. A multifactorial relationship exists between total circulating cell-free DNA levels and maternal BMI[J]. Prenat Diagn, 2012, 32(9): 912-914.
[22]
Wang E, Batey A, Struble C, et al. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma[J]. Prenat Diagn, 2013, 33(7): 662-666.
[23]
Ashoor G, Poon L, Syngelaki A, et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks′ gestation: effect of maternal and fetal factors[J]. Fetal Diagn Ther, 2012, 31(4): 237-243.
[24]
Bianchi DW, Prosen T, Platt LD, et al. Massively parallel sequencing of maternal plasma DNA in 113 cases of fetal nuchal cystic hygroma[J]. Obstet Gunecol, 2013, 121(5): 1057-1062.
[25]
Mazloom AR, Dzakula Z, Oeth P, et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma[J]. Prenat Diagn, 2013, 33(6): 591-597.
[1] 武玺宁, 欧阳云淑, 张一休, 孟华, 徐钟慧, 张培培, 吕珂. 胎儿心脏超声检查在抗SSA/Ro-SSB/La抗体阳性妊娠管理中的应用[J]. 中华医学超声杂志(电子版), 2023, 20(10): 1056-1060.
[2] 杨水华, 何桂丹, 覃桂灿, 梁蒙凤, 罗艳合, 李雪芹, 唐娟松. 胎儿孤立性完全型肺静脉异位引流的超声心动图特征及高分辨率血流联合时间-空间相关成像的应用[J]. 中华医学超声杂志(电子版), 2023, 20(10): 1061-1067.
[3] 赵红娟, 赵博文, 潘美, 纪园园, 彭晓慧, 陈冉. 应用多普勒超声定量分析正常中晚孕期胎儿左心室收缩舒张时间指数[J]. 中华医学超声杂志(电子版), 2023, 20(09): 951-958.
[4] 张璟璟, 赵博文, 潘美, 彭晓慧, 毛彦恺, 潘陈可, 朱玲艳, 朱琳琳, 蓝秋晔. 胎儿超声心动图测量McGoon指数在评价胎儿肺血管发育中的应用[J]. 中华医学超声杂志(电子版), 2023, 20(08): 860-865.
[5] 旺久, 陈军, 朱霞, 米玛央金, 赵胜, 陈欣林, 李建华, 王双. 山南市妇幼保健院开展胎儿系统超声筛查的效果分析[J]. 中华医学超声杂志(电子版), 2023, 20(07): 728-733.
[6] 徐鹏, 李军, 高巍伦, 王峥, 庞珅, 李春妮, 朱霆. 快速旋转扫查法在胎儿超声心动图检查中的应用价值[J]. 中华医学超声杂志(电子版), 2023, 20(07): 761-766.
[7] 谭芳, 杨娇娇, 沈玉琴, 李炎菲海, 王海蕊, 范思涵, 纪学芹. 胎儿心脏定量分析技术对正常胎儿心脏形态及收缩功能的评价[J]. 中华医学超声杂志(电子版), 2023, 20(06): 598-604.
[8] 罗刚, 泮思林, 陈涛涛, 许茜, 纪志娴, 王思宝, 孙玲玉. 超声心动图在胎儿心脏介入治疗室间隔完整的肺动脉闭锁中的应用[J]. 中华医学超声杂志(电子版), 2023, 20(06): 605-609.
[9] 黄佳, 石华, 张玉国, 胡佳琪, 陈茜. 胎儿左头臂静脉正常与异常超声图像特征及其临床意义[J]. 中华医学超声杂志(电子版), 2023, 20(06): 610-617.
[10] 袁泽, 庄丽. 超声检测胎儿脐动脉和大脑中动脉血流对胎儿宫内窘迫的诊断价值[J]. 中华医学超声杂志(电子版), 2023, 20(06): 618-621.
[11] 刘镭, 杨昕, 许晓华, 林胜谋, 熊初琴, 农丽录, 董振宇, 李胜利. 中孕期胎儿鼻前皮肤厚度及鼻骨长度筛查胎儿染色体病的临床价值[J]. 中华医学超声杂志(电子版), 2023, 20(05): 506-510.
[12] 李博, 孔德璇, 彭芳华, 吴文瑛. 超声在胎儿肺静脉异位引流诊断中的应用价值[J]. 中华医学超声杂志(电子版), 2023, 20(04): 437-441.
[13] 薛超, 张烨, 赵映, 韩建成, 谷孝艳, 孙琳, 刘晓伟, 宋伟, 何怡华. 胎儿先天性肺动脉瓣缺如综合征的超声特征及预后分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 410-418.
[14] 刘磊, 王优, 黄锐斌, 张丽娜, 宋一丹, 雷婷缨. 染色体微阵列分析技术在股骨长度偏短胎儿遗传学诊断中的应用[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 437-445.
[15] 邹艳丽, 栾文杰, 王淑娟, 刘亚琴, 初桂芝, 李松洋, 王好玲, 张锦婷, 姜鑫, 栾泽东. 早孕期胎儿右位主动脉弓的产前超声诊断学特征[J]. 中华诊断学电子杂志, 2023, 11(04): 227-232.
阅读次数
全文


摘要